Compare Neurocrine Biosciences Inc (NBIX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Waste Management, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Waste Management, Inc. trades at $217.1 (market cap $87.05B). The key difference: Waste Management, Inc. is far larger — about 5.5× Neurocrine Biosciences Inc's market cap, and Waste Management, Inc. pays a 1.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WM | |
|---|---|---|
Market Cap | $15.77B | $87.05B |
Sector | Health | Industrials |
52-Week High | $185.50 | $246.51 |
52-Week Low | $123.10 | $196.77 |
Enterprise Value | $15.78B | $109.85B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
WM trades at $217.78, down 0.55% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing Q4 2025. Revenue grew to $25.20B in 2025, with strong profitability margins. Analysts maintain a buy consensus with a $263.43 price target, though technical indicators show near-term pressure.
The outlook is supported by steady waste-service demand and sustainability investments, but high debt levels and valuation concerns pose risks. CEO transition adds uncertainty, while institutional buying signals confidence. Upside exists if execution aligns with analyst targets, but investors should weigh premium valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
